Auro Laboratories

Auro Laboratories Financial Leverage

The Financial Leverage (Equity Multiplier) of Auro Laboratories (530233.BO) as of Oct 18, 2026 is 2.61. In the previous year, Financial Leverage (Equity Multiplier) was 2.31 — a change of 13.28% (higher).

Financial Leverage

2.61

YoY

13.28%

Last updated:

Financial Leverage (Equity Multiplier) of Auro Laboratories is 2026 2.61 . Financial Leverage (Equity Multiplier) of Auro Laboratories was 2025 2.31 . It decreases by 13.28% higher compared to the previous year.

The Auro Laboratories Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2019
1.92 INR
Jan 1, 2020
1.50 INR
Jan 1, 2021
1.47 INR
Jan 1, 2022
1.74 INR
Jan 1, 2023
1.64 INR
Jan 1, 2024
2.04 INR
Jan 1, 2025
2.31 INR
Jan 1, 2026
2.61 INR
The Auro Laboratories Financial Leverage history
YEARFinancial LeverageYoY
2.61+13.28%
2.31+12.87%
2.04+24.80%
1.64-6.10%
1.74+18.96%
1.47-2.60%
1.50-21.71%
1.92-17.96%
2.34-17.73%
2.85-4.34%
2.98-20.32%
3.74-3.95%
3.89—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Auro Laboratories Stock analysis

What does Auro Laboratories do? Auro Laboratories Ltd is a pharmaceutical company headquartered in Mumbai, India. The company engages in the manufacture of active pharmaceutical ingredients (APIs), intermediates, and generic formulations. It operates primarily within the Pharmaceuticals sector. Auro Laboratories offers APIs across various therapeutic categories, including antihistamines, muscle relaxants, diuretics, iron deficiency treatments, anti-diabetics, anti-fungals, anti-ulcer medications, iodine supplements, anti-malarials, analgesics, antacids, and anti-inflammatories. The company also produces intermediates such as Glibenclamide Sulphonamide, Cis-bromo benzoate, Cls-Tosylate, 2-Ethoxy Benzoic Acid, 3,4,5-Trimethoxy Benzoic Acid, and 5-Bromo Phthalide. Additionally, Auro Laboratories provides toll and custom manufacturing services for APIs and intermediates on a contract basis. The company has an international presence, with a significant portion of its production exported to Southeast Asia, the Middle East, and various European countries. Key export destinations include Egypt, Germany, Malaysia, Singapore, South Africa, Brazil, Spain, and the United Kingdom. Auro Laboratories went public with its IPO on March 7, 1995. The company's website is http://www.aurolabs.com/. Auro Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Auro Laboratories stock

Financial Leverage (Equity Multiplier) of Auro Laboratories is 2.61 in 2026.

Financial Leverage (Equity Multiplier) of Auro Laboratories changed from 2.31 to 2.61, representing a 13.28% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Auro Laboratories since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Auro Laboratories with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — Auro Laboratories

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — Auro Laboratories